Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608780 | 1.00 | HTT (0.54) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2792830 | 1.00 | HTT (0.54) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL242244 | 1.00 | HTT (0.54) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29706163 | 1.00 | HTT (0.54) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29484110 | 1.00 | HTT (0.54) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2999173 | 0.98 | HTT (0.53) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8944136 | 0.98 | HTT (0.53) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1844342 | 0.95 | HTT (0.49) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Ethylenediamine SCHEMBL10773019 | 0.92 | HTT (0.48) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2529181 | 0.91 | LMNA (0.51) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-117263931-A | Method for preparing palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-114573411-A | Preparation method of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid | 福建福瑞明德药业有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-216396304-U | Refining plant is used in production of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid | 福建福瑞明德药业有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-113105447-A | Preparation method of high-purity palonosetron hydrochloride | 昆明源瑞制药有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-107417525-B | Method for chiral preparation of (S) -tetrahydro-1-naphthoic acid and derivatives thereof | 杭州新博思生物医药有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-111620777-A | Resolution method of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid | 成都蓝蜻蜓生物技术有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-108178756-B | Preparation method of palonosetron hydrochloride and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-108084176-A | Preparation method of high-purity palonosetron hydrochloride | 昆明源瑞制药有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-101186607-A | Method for synthesizing palonosetron hydrochloride | SHENZHEN NEPTUNUS PHARMACEUTIC (CN) | 2008-05-28 | — | — | CN | claimed |
| US-12289941-B2 | Chiral heterostructures | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| US-12065428-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118108706-A | Glutarimide | C4医药公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-1907361-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | Devgen N.V. (BE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| US-5576434-A | (1-azabicyclo[2.2.2]oct-3-yl) (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)amine and n-(1-azabicyclo[2.2.2]oc | HELSINN HEALTHCARE SA (CH) | 1996-11-19 | — | — | US | disclosed |
| US-5510486-A | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one | SYNTEX (U.S.A.) INC. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065428-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | HTT 1108/4885MEN1 1494/4885KMT2A 4121/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | HTT 3045/4885MEN1 2114/4885KMT2A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.